

*LIMITED REVIEW REPORT*

*To the Board of Directors  
Anglo-French Drugs & Industries Limited,  
41, 3<sup>rd</sup> Cross, V Block, Rajajinagar,  
Bangalore – 560 010.*

We have Reviewed the accompanying statement of Unaudited financial results of Anglo-French Drugs & Industries Limited for the quarter ended 30<sup>th</sup> June 2016 except for the disclosures regarding 'Public Shareholding' and Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors their meeting held on 9<sup>th</sup> August, 2016. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner, in which it is to be disclosed, or that it contains any material misstatement.

For RAY & RAY  
Chartered Accountants

*Mrinal Kanti Bandyopadhyay*

MRINAL KANTI BANDYOPADHYAY  
Partner

Membership No. 051472  
Firm Registration No.301072E

Place: Bangalore  
Date: 9<sup>th</sup> August, 2016



SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED

PARTICULARS	(in ₹ lacs, except equity share and per equity share data)			
	3 months ended (30/06/2016) (Un audited)	Preceding 3 months ended (31/03/2016) (Audited)	Corresponding 3 months ended in the previous year (30/06/2015) (Unaudited)	Previous year ended (31/03/2016) Audited
1. Income from Operations (a) Net Sales / Income from Operations (Net of Excise Duty) (b) Other Operating Income	2925 25	2812 66	2587 57	11260 219
Total Income from operations (Net) (a+b)	2950	2878	2644	11479
2. Expenses				
a. Cost of Materials Consumed	1159	940	696	3520
b. Purchase of Stock in Trade	727	727	534	2361
c. Changes in Inventories of Finished goods, work in progress & Stock in Trade	(213)	(24)	17	(73)
d. Employee Benefits Expense	569	518	484	2065
e. Depreciation and Amortisation Expense	42	36	42	160
f. Other Expenses	716	791	774	3256
Total Expenses	3001	2988	2547	11288
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2)	(51)	(110)	97	192
4. Other Income	7	55	9	123
5. Profit/(Loss) (from Ordinary activities before Finance Costs and Exceptional items (3+4)	(44)	(55)	106	314
6. Finance Costs	80	(24)	74	201
7. Profit/(Loss) from Ordinary activities before Finance Costs but before Exceptional Items (5-6)	(124)	(31)	32	113
8. Exceptional Items	0	0	0	0
9. Profit/(+)/Loss(-) from Ordinary Activities before Tax (7+8)	(124)	(31)	32	113
10. Tax Expense	0	0	0	0
11. Net Profit(+)/Loss(-) from Ordinary Activities after Tax (9-10)	(124)	(31)	32	46
12. Extraordinary Item (net of tax expenses)	0	0	0	0
13. Net Profit(+)/Loss(-) for the period	(124)	(31)	32	46
14. Paid up equity share capital (Face Value - 10/-each)	116	116	116	116
15. Reserves excluding revaluation reserve	1447	1613	1557	1570
16. Earning per share (in ₹)				
a) Basic and Diluted before Extraordinary Item	(10.64)	(2.75)	2.74	3.93
b) Basic and Diluted after Extraordinary Item	(10.64)	(2.75)	2.74	3.93

**For RAY & RAY**  
Chartered Accountants  
F.R. No. 301072E

*Minist Kant. Bandyopadhyay*  
(Minist Kant Bandyopadhyay)  
Partner  
M. No. 051472

*Handwritten signature*

PARTICULARS	As at 31st March 2016 (Un-audited)	As at 31st March 2015 (Audited) (July 14 - March 15)
<b>A. EQUITY AND LIABILITIES</b>		
1. Shareholder's Funds		
(a) Share Capital	116	116
(b) Reserves and Surplus	1447	1570
(c) Money received against share warrants		
2. Non-Current Liabilities		
(a) Long-term borrowings	595	716
(b) Deferred tax liabilities (Net)	163	163
(c) Other Long term liabilities	312	324
(d) Long term provisions	0	41
3. Current Liabilities		
(a) Short-term borrowings	1740	1634
(b) Trade payables	2597	2179
(c) Other current liabilities	1447	1045
(d) Short-term provisions	259	218
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>8676</b>	<b>8003</b>
<b>B ASSETS</b>		
1. Non-current assets		
(a) Fixed assets		
(i) Fixed assets	1827	1841
(ii) Non-current investments	47	47
(c) Long term loans and advances	79	78
(d) Other non-current assets	0	0
2. Current assets		
(a) Inventories	2171	1877
(b) Trade receivables	3015	2876
(c) Cash and cash equivalents & other bank balances	97	98
(d) Short-term loans and advances	1326	1092
(e) Other current assets	113	94
<b>TOTAL ASSETS</b>	<b>8676</b>	<b>8003</b>

Particulars	Nil
<b>INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	Nil

Notes:  
 1. The above financial results were taken on record by the Board of Directors in their Meeting held on 9th August, 2016  
 2. The figures in respect of previous period have been regrouped/recast wherever necessary.

**FOR RAY & RAY**  
 Chartered Accountants  
 F. R. No. 301072E

Place: Bengaluru  
 Date: 9th August 2016

*Mrinal Kanti Bandyopadhyay*  
**(Mrinal Kanti Bandyopadhyay)**  
 Partner  
 M. No. 051472

ANGLO-FRENCH DRUGS & INDUSTRIES LTD

*Abhaya Kanoria*  
**(ABHAYA KANORIA)**  
 CHAIRMAN & MANAGING DIRECTOR